MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 11-14-2025
STRATA Skin Sciences Gross Profit 2011-2026 | SSKN
Gross profit is a key indicator of how efficiently a company produces or sells its products. This metric helps assess a business’s ability to generate revenue at the initial stage, before accounting for all other expenses. Regular analysis of gross profit allows companies to respond in a timely manner to changes in cost of goods, pricing strategy, and market conditions.
Calculation formula:Importance for business:
Gross Profit = Revenue – Cost of Goods Sold (COGS)
Revenue — all cash inflows from the sale of goods or services.
Cost of Goods Sold — direct costs related to the production or acquisition of goods:
- Raw materials and supplies
- Wages of production personnel
- Depreciation of equipment
- Transportation and warehousing costs (if directly related to production)
- Assessing core business profitability
If gross profit is declining, it may indicate rising production costs or falling sales. - Financial planning
Gross profit is the basis for calculating other key metrics, such as operating and net profit. - Benchmarking against competitors
Gross profit analysis helps compare the efficiency of different companies within the same industry. - Insights into pricing effectiveness
If gross profit is low, the company may be pricing too low or failing to control costs effectively.
- Increase in raw material and supply costs
- Rising production expenses
- Price reductions due to competition
- Decrease in sales volume
- Currency exchange rate fluctuations (for imports/exports)
Gross profit is an important metric, but it does not provide a complete picture of a company’s financial health, as it does not account for administrative and selling expenses, taxes, debt burden, or depreciation.
Annual Gross Profit STRATA Skin Sciences
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 21.8 M | 19.8 M | 14.1 M | 20.3 M | 17.1 M | 18 M | 19.1 M | 4.78 M | -4.02 M | -3.8 M | -1.76 M | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 21.8 M | -4.02 M | 11.4 M |
Quarterly Gross Profit STRATA Skin Sciences
| 2025-Q3 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 4.18 M | - | 5.29 M | 4.94 M | 3.08 M | - | 4.95 M | 4.32 M | 4.39 M | - | 5.8 M | 4.99 M | 4.13 M | - | 5.38 M | 4.76 M | 3.71 M | - | 3.23 M | 1.96 M | 4.4 M | - | 4.62 M | 4.91 M | 4.61 M | - | 4.63 M | 3.84 M | 3.39 M | - | 4.18 M | 5.27 M | 4.54 M | - | 4.7 M | 4.6 M | 4.2 M | - | 5.28 M | -5.86 M | -630 K | - | -1.34 M | -1.05 M | -821 K | - | -1.87 M | -1.24 M | -936 K | - | -500 K | -296 K | -119 K | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 5.8 M | -5.86 M | 2.84 M |
Gross Profit of other stocks in the Medical devices industry
| Issuer | Gross Profit | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Aethlon Medical
AEMD
|
1.36 M | $ 2.21 | 4.74 % | $ 3.45 M |  USA |
 |
AdaptHealth Corp.
AHCO
|
89.3 M | $ 10.52 | 0.96 % | $ 1.42 B | USA |
 |
Allied Healthcare Products
AHPI
|
443 K | - | 3.58 % | $ 2.21 M | USA |
 |
GenMark Diagnostics, Inc.
GNMK
|
67.9 M | - | - | $ 1.77 B | USA |
 |
Acutus Medical
AFIB
|
-3.14 M | - | -26.83 % | $ 2.62 M | USA |
 |
Butterfly Network
BFLY
|
48.8 M | $ 4.26 | 8.68 % | $ 902 M | USA |
 |
Alphatec Holdings
ATEC
|
532 M | $ 12.96 | 2.82 % | $ 1.94 B | USA |
 |
Obalon Therapeutics, Inc.
OBLN
|
584 K | - | -5.86 % | $ 30.6 M | USA |
 |
Aziyo Biologics
AZYO
|
6.6 M | - | 1.37 % | $ 20.5 M | USA |
 |
Cognyte Software Ltd.
CGNT
|
247 M | $ 8.36 | -0.24 % | $ 600 M |  Israel |
 |
Avinger
AVGR
|
2 M | - | -20.74 % | $ 369 K | USA |
 |
BIOLASE
BIOL
|
16.7 M | - | -13.19 % | $ 166 K | USA |
 |
Boston Scientific Corporation
BSX
|
13.9 B | $ 71.04 | 1.79 % | $ 105 B | USA |
 |
CONMED Corporation
CNMD
|
750 M | $ 37.05 | -0.96 % | $ 1.15 B | USA |
 |
Conformis
CFMS
|
23.2 M | - | - | $ 16.4 M | USA |
 |
Cytosorbents Corporation
CTSO
|
25.1 M | $ 0.69 | 6.31 % | $ 37.6 M | USA |
 |
EDAP TMS S.A.
EDAP
|
26.6 M | $ 4.07 | 2.67 % | $ 152 M |  France |
 |
Apollo Endosurgery
APEN
|
42.4 M | - | - | $ 475 M | USA |
 |
Cutera
CUTR
|
-12.7 M | - | -10.19 % | $ 1.99 M | USA |
 |
Establishment Labs Holdings
ESTA
|
146 M | $ 64.79 | 2.06 % | $ 1.92 B |  Costa-rica |
 |
CryoLife, Inc.
CRY
|
168 M | - | -4.14 % | $ 702 M | USA |
 |
Dynatronics Corporation
DYNT
|
6.01 M | - | 14.99 % | $ 929 K | USA |
 |
ClearPoint Neuro
CLPT
|
19.1 M | $ 11.32 | 2.58 % | $ 306 M | USA |
 |
Axonics Modulation Technologies
AXNX
|
198 M | - | - | $ 3.31 B | USA |
 |
Hancock Jaffe Laboratories, Inc.
HJLI
|
4.25 K | - | -1.98 % | $ 98.3 M | USA |
 |
Itamar Medical Ltd.
ITMR
|
28.7 M | - | 0.03 % | $ 1.58 B | Israel |
 |
Misonix, Inc.
MSON
|
43.7 M | - | - | $ 462 M | USA |
 |
Neovasc
NVCN
|
1.99 M | - | - | $ 111 M |  Canada |
 |
FONAR Corporation
FONR
|
42.4 M | $ 18.43 | 0.05 % | $ 121 M | USA |
 |
Helius Medical Technologies
HSDT
|
61 K | $ 2.19 | - | $ 1.33 M | USA |
 |
GBS
GBS
|
1.25 M | - | -0.57 % | $ 7.12 M | USA |
 |
InMode Ltd.
INMD
|
291 M | $ 13.62 | 1.34 % | $ 880 M | Israel |
 |
IRIDEX Corporation
IRIX
|
21.8 M | $ 1.34 | 0.75 % | $ 21.6 M | USA |
 |
Intersect ENT, Inc.
XENT
|
50.2 M | - | - | $ 955 M | USA |
 |
Abbott Laboratories
ABT
|
18.7 B | $ 111.04 | 0.99 % | $ 193 B | USA |
 |
Delcath Systems
DCTH
|
73.4 M | $ 9.77 | -0.41 % | $ 350 M | USA |
 |
Bio-Rad Laboratories
BIO
|
342 M | $ 269.42 | 3.13 % | $ 7.6 B | USA |
 |
LivaNova PLC
LIVN
|
940 M | $ 62.57 | 1.86 % | $ 3.41 B |  Britain |
 |
Integra LifeSciences Holdings Corporation
IART
|
953 M | $ 9.11 | 1.05 % | $ 702 M | USA |
 |
AxoGen
AXGN
|
167 M | $ 32.77 | -0.23 % | $ 1.51 B | USA |
 |
Align Technology
ALGN
|
2.8 B | $ 176.42 | 4.11 % | $ 13.2 B | USA |
 |
Bruker Corporation
BRKR
|
1.65 B | $ 33.71 | 2.9 % | $ 5.02 K | USA |
 |
MiMedx Group
MDXG
|
346 M | $ 4.37 | -1.02 % | $ 646 M | USA |
 |
BioSig Technologies
BSGM
|
229 K | - | 37.08 % | $ 85.7 M | USA |
 |
Apyx Medical Corporation
APYX
|
33 M | $ 3.74 | 1.91 % | $ 154 M | USA |
 |
OrthoPediatrics Corp.
KIDS
|
173 M | $ 17.22 | 0.64 % | $ 404 M | USA |
 |
Integer Holdings Corporation
ITGR
|
500 M | $ 86.6 | 2.95 % | $ 3.01 B | USA |